Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

Zymeworks Inc. (NYSE:ZYME) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zymeworks in a research report issued on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

Several other equities analysts have also issued reports on ZYME. HC Wainwright boosted their price target on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Monday, March 10th. Wells Fargo & Company raised their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. Citigroup upped their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price for the company in a research note on Monday, December 16th. Finally, Lifesci Capital started coverage on shares of Zymeworks in a report on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.00.

Zymeworks Stock Down 1.6 %

Shares of ZYME stock opened at $12.72 on Thursday. The firm has a market cap of $885.02 million, a PE ratio of -8.48 and a beta of 1.13. Zymeworks has a 12 month low of $7.97 and a 12 month high of $17.70. The stock has a 50 day moving average of $13.72 and a 200-day moving average of $13.68.

Insider Transactions at Zymeworks

In related news, Director Ecor1 Capital, Llc acquired 11,958 shares of the business’s stock in a transaction dated Tuesday, December 24th. The stock was bought at an average price of $14.12 per share, with a total value of $168,846.96. Following the acquisition, the director now owns 14,704,239 shares in the company, valued at $207,623,854.68. This represents a 0.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey T. L. Smith sold 11,110 shares of Zymeworks stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $165,761.20. Following the completion of the transaction, the executive vice president now directly owns 8,890 shares of the company’s stock, valued at approximately $132,638.80. This trade represents a 55.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 1,507,168 shares of company stock valued at $19,339,774 and sold 89,601 shares valued at $1,336,847. 1.92% of the stock is owned by insiders.

Institutional Trading of Zymeworks

Several institutional investors and hedge funds have recently bought and sold shares of ZYME. Sterling Capital Management LLC increased its stake in shares of Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock worth $25,000 after purchasing an additional 1,524 shares during the period. AlphaQuest LLC raised its position in shares of Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after buying an additional 2,324 shares in the last quarter. FMR LLC lifted its stake in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after purchasing an additional 1,525 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Zymeworks during the 4th quarter worth $108,000. Finally, Tower Research Capital LLC TRC increased its position in Zymeworks by 343.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock worth $142,000 after purchasing an additional 7,518 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.